SALT LAKE CITY, September 5, 2016 – Elute, Inc, an emerging leader in developing a new class of polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections, announced today that Jon Serbousek, former Sr. Vice President of Biomet, inc. (now Zimmer Biomet), was appointed to its Board of Directors. Mr. Serbousek’s addition to the Elute Board comes at a time when the Company transitions from the pre-clinical stage to the clinical stage of evaluating its novel antibiotic eluting bone void fillers for prevention and treatment of bone infections, prior to its commercial launch.

As a senior executive at Biomet prior to its 2015 merger with Zimmer, Inc., Mr. Serbousek was a worldwide innovator and leader in the design and manufacture of products for the orthopedic, orthopedic reconstructive, biologic, trauma, extremities and sports medicine. During his tenure at Biomet, he had full P&L responsibility for billion dollar enterprises as President of U.S. Orthopedics, Worldwide Group President of Orthopedics and Worldwide President of Biomet Biologics. “We are very pleased that Jon has joined Elute’s Board,” said Ashok C. Khandkar, Ph.D., Chief Executive Officer of Elute. “Jon’s broad experience has particular relevance for Elute at this time, as we move forward towards the first-in-man clinical evaluations of our products. His success as an operational innovator will add to the depth of our Board as we transition Elute from research and development into a clinical stage company.”

Prior to Biomet, Mr. Serbousek held various senior management positions with Medtronic’s spinal and biologics business, to include, Division President; Spine and International and most recently as Worldwide Vice President and General Manager, Biologics. Before joining Medtronic, Mr. Serbousek served as Vice President of Marketing and Product Development for DePuy Orthopedics, a Johnson and Johnson Company. He earned a B.S. in Engineering from Washington State University and a Masters of Science degree in Bioengineering from the University of Utah. Mr. Serbousek later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.

“Elute’s technology employs patented and patent-pending polymer – ceramic composites to address one of the biggest problems in treating bone infections worldwide – delivering a controlled and sustained level of antibiotics within a therapeutic window for 6-8 weeks,” commented Mr. Serbousek. “I am pleased to work with Elute’s experienced team to realize the promise of its technology and help transform the Company into a commercial business that creates lasting value and makes an important difference in the lives of patients and families globally.”

“I also look forward to Mr. Serbousek’s contributions to our Board and to working with him as we further develop and execute the Company’s strategy to become a global leader in controlled and sustained delivery of antibiotics for treatment of bone infections,” said Dennis B. Farrar, Executive Chairman and co-founder of Elute.

About Elute, Inc.

Elute, Inc. is a private medical device company developing innovative polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections. Elute’s products provide a clinically relevant delivery of antibiotics and other therapeutic agents directly into surgical sites of patients undergoing orthopedic and other procedures. Elute’s first product candidate, undergoing orthopedic and other procedures. Elute’s first product candidate, ElutiBone™, has demonstrated the controlled release of certain antibiotics in a therapeutic range for a 6-8 week period. The Company has assembled a strong management team, Board of Directors and Clinical Advisory Board with significant clinical and commercial development experience. Elute, Inc. is located in Salt Lake City, Utah. For more information, please visit the Company’s website at www.elutinc.com.